Annual Report

Overview

The report presents the company's FY 2018-19 strategy reset and resurgent performance, including 6% revenue growth and 7% EBITDA growth. It covers acquisitions of Vensun and Pharmapar and the conversion of the Vivimed joint venture to full ownership. The company reports CSR spending of ₹25.84 Million across health, education and employability initiatives.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2018-2019
Period: Ends 31 March 2019
Publication date: 10 May 2019
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services